Compare USFD & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USFD | INCY |
|---|---|---|
| Founded | 2007 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7B | 17.0B |
| IPO Year | 2016 | 1994 |
| Metric | USFD | INCY |
|---|---|---|
| Price | $92.33 | $97.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 20 |
| Target Price | $103.64 | ★ $104.05 |
| AVG Volume (30 Days) | ★ 2.1M | 1.3M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 45.54 | ★ 4173.33 |
| EPS | 2.94 | ★ 6.41 |
| Revenue | ★ $39,424,000,000.00 | $3,394,635,000.00 |
| Revenue This Year | $7.63 | $10.48 |
| Revenue Next Year | $3.92 | $10.99 |
| P/E Ratio | $31.04 | ★ $14.91 |
| Revenue Growth | 4.08 | ★ 13.67 |
| 52 Week Low | $60.46 | $56.16 |
| 52 Week High | $102.13 | $112.29 |
| Indicator | USFD | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 53.78 | 57.62 |
| Support Level | $87.44 | $82.66 |
| Resistance Level | $94.27 | $108.79 |
| Average True Range (ATR) | 2.09 | 2.48 |
| MACD | 0.10 | 0.79 |
| Stochastic Oscillator | 76.65 | 97.19 |
US Foods Holding Corp is a U.S. food service distributor that distributes food and nonfood products to the healthcare and hospitality industries, restaurants, education, government facilities, and grocers. It has various customer locations across the United States, with a vast network of distribution facilities, a fleet of trucks, and cash and carry locations offering food and non-food products, and a comprehensive suite of e-commerce, technology, and business solutions to its customers. The company operates in one business segment in which it markets, sells, and distributes fresh, frozen, and dry food and non-food products to foodservice customers throughout the U.S. The products offered are as snacks, beverages, fresh produce, sauces, condiments, canned/frozen fruits and others.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.